Asset Manager

Updated:

Jade Biosciences

Jade Biosciences develops therapies for autoimmune diseases within the biotechnology sector. The company creates treatments for patients with these conditions.

Jade Biosciences

Jade Biosciences develops therapies for autoimmune diseases within the biotechnology sector. The company creates treatments for patients with these conditions. Founded in 2024, Jade Biosciences is based in Philadelphia, Pennsylvania.

General information

Firm type

Asset Manager

Location

Region

North America

Country

United States

City

Philadelphia

Corporate office

Philadelphia, United States

Principals

Tom Frohlich

Chief Executive Officer

Andrew King

President, Research & Development

Edward R. Conner

Chief Medical Officer

Brad Dahms

Chief Financial Officer

Eric Dobmeier

Board Chair and Venture Partner, Samsara Biocapital

Chris Cain

Director of Research, Fairmount

Tomas Kiselak

Founding Partner, Fairmount

Lawrence Klein

Chief Executive Officer, Oruka Therapeutics

Erin Lavelle

Former COO and CFO, ProfoundBio and Eliem Therapeutics

Sector focus

Digital HealthHealthcare Services

Frequently asked questions

How does Jade Biosciences source its drug candidates?

Jade does not maintain an internal research lab. The company exclusively in-licenses discovery-stage assets from Paragon Therapeutics, an antibody discovery engine founded by Fairmount. This creates a pipeline without the capital outlay typical of early-stage biologics research.

What is Jade's sole publicly disclosed drug program?

JADE101 is the only named asset. The drug is designed to inhibit the cytokine APRIL and is being developed for immunoglobulin A nephropathy (IgAN). The company does not specify a timeline for clinical data or additional indications in its public materials.

Profile maintained by using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.

Need institutional-grade insight on asset managers?

Altss delivers:

Principals with verified direct contactsAllocation history by asset classOSINT-derived deal signals
Book a demo

Prefer a guided tour?

We’ll walk you through:

Interactive funding timelinesCustom mandate & allocation filters
Book a demo

More Philadelphia Asset Manager profiles